Zobrazeno 1 - 10
of 232
pro vyhledávání: '"Shigeo, Horiike"'
Autor:
Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yuji Shimura, Yoshiaki Chinen, Kazuna Tanba, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Daichi Nishiyama, Reiko Isa, Junko Yamaguchi, Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 5185-5199 (2020)
Abstract RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non‐Hodgkin lymphoma. In this study, ser
Externí odkaz:
https://doaj.org/article/9e1e7146637b4917811ff4b9c406b974
Autor:
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple my
Externí odkaz:
https://doaj.org/article/bdff3f7ce0164c809dccfaff7fdd38f3
Autor:
Yoshimi Mizuno, Taku Tsukamoto, Eri Kawata, Nobuhiko Uoshima, Hitoji Uchiyama, Isao Yokota, Saori Maegawa, Tomoko Takimoto, Kazuna Tanba, Yayoi Matsumura‐Kimoto, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Mio Yamamoto‐Sugitani, Yoshiaki Chinen, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
Publikováno v:
Cancer Medicine, Vol 7, Iss 3, Pp 655-664 (2018)
Abstract Diffuse large B‐cell lymphoma (DLBCL), which is the most prevalent disease subtype of non‐Hodgkin lymphoma, is highly heterogeneous in terms of cytogenetic and molecular features. This study retrospectively investigated the clinical impa
Externí odkaz:
https://doaj.org/article/5970ece3c6544cbb98a7014cb94e5845
Autor:
Junko Yamaguchi, Takahiro Fujino, Reiko Isa, Daichi Nishiyama, Saeko Kuwahara-Ota, Yuka Kawaji, Taku Tsukamoto, Yoshiaki Chinen, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Kei Kohno, Shigeo Nakamura, Junya Kuroda
Publikováno v:
Haematologica, Vol 104, Iss 8 (2019)
Externí odkaz:
https://doaj.org/article/65fc80779c1d4266a977513eb1b533d7
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms. Despite recent improvement in the treatment outcome of multiple myeloma by novel molecular-targeted chemotherapeutics, multiple myeloma remains incur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0a936df6271f349bf451e73ad0bd1e
https://doi.org/10.1158/1535-7163.c.6535282
https://doi.org/10.1158/1535-7163.c.6535282
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 62K, Chromosomal abnormalities and signaling molecule expression in myeloma-derived cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11deddfc12514842deb3f6aaaec838c3
https://doi.org/10.1158/1535-7163.22496473
https://doi.org/10.1158/1535-7163.22496473
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 141K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b19f0202eb224641e587fe3cde47af9
https://doi.org/10.1158/1535-7163.22496476.v1
https://doi.org/10.1158/1535-7163.22496476.v1
Autor:
Masafumi Taniwaki, Mitsuomi Hirashima, Akira Yamauchi, Shinya Kimura, Shigeo Horiike, Yuji Shimura, Nana Sasaki, Tsutomu Kobayashi, Hisao Nagoshi, Mio Yamamoto, Junya Kuroda
Supplementary Table S1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012b6fa5ee159b5a3378c1d80917eed4
https://doi.org/10.1158/1541-7786.22518723.v1
https://doi.org/10.1158/1541-7786.22518723.v1
Autor:
Masafumi Taniwaki, Mitsuomi Hirashima, Akira Yamauchi, Shinya Kimura, Shigeo Horiike, Yuji Shimura, Nana Sasaki, Tsutomu Kobayashi, Hisao Nagoshi, Mio Yamamoto, Junya Kuroda
Tyrosine kinase inhibitors (TKI) against Bcr-Abl are the first-line therapeutics for chronic myelogenous leukemia (CML). However, the resistance to Bcr-Abl TKIs is induced in leukemic cells not only by loss of sensitivity to TKIs through Bcr-Abl–re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adca77031fdf90b56aa04f4f2912c7b9
https://doi.org/10.1158/1541-7786.c.6542094
https://doi.org/10.1158/1541-7786.c.6542094
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 75K, Clinical information for patient-derived primary myeloma cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8b5408b5eca5f35cfdcde9da6f48b8
https://doi.org/10.1158/1535-7163.22496470.v1
https://doi.org/10.1158/1535-7163.22496470.v1